Literature DB >> 24225339

Assessment of operability of patients with pulmonary arterial hypertension associated with congenital heart disease.

Patrick O Myers1, Cécile Tissot, Maurice Beghetti.   

Abstract

Pulmonary arterial hypertension (PAH) is a common complication of congenital heart disease, and is now predominantly among patients with uncorrected left-to-right shunts. A growing population is characterized by persistent or recurrent PAH after surgical or interventional correction of left-to-right shunts; the latter having a worse prognosis than other forms of PAH associated with congenital heart disease. New treatments for PAH have been shown to be effective in improving PAH exercise capacity and hemodynamics, raising the hope for making previously inoperable congenital heart defects operable and shifting the framework for the assessment of operability. This review focuses on current methods for assessing operability in PAH associated with congenital heart disease, and the possibility of "treat-and-repair" vs. "repair-and-treat" strategies for patients with inoperable or borderline PAH.

Entities:  

Mesh:

Year:  2013        PMID: 24225339     DOI: 10.1253/circj.cj-13-1263

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  19 in total

1.  Pulmonary Hypertension in Children - a Practical Approach.

Authors:  Eliza Cinteza; Alin Nicolescu; Cristina Filip; Andrei Lupu; Georgiana Nicolae; Gabriela Duica; Mihaela Balgradean
Journal:  Maedica (Buchar)       Date:  2015-09

2.  EXPRESS: Parameters associated with outcome in pediatric patients with congenital heart disease and pulmonary hypertension subjected to combined vasodilator and surgical treatments.

Authors:  Ana Maria Thomaz; Luiz Junya Kajita; Vera D Aiello; Leína Zorzanelli; Filomena Rbg Galas; Cleide G Machado; Miguel Barbero-Marcial; Marcelo B Jatene; Marlene Rabinovitch; Antonio Augusto Lopes
Journal:  Pulm Circ       Date:  2019-02-26       Impact factor: 3.017

3.  Closure of an atrial septal defect with a one-way flap patch in a patient with severe pulmonary hypertension.

Authors:  Milenko Rosic; Stamenko Susak; Aleksandar Redzek; Lazar Velicki
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-02-25

4.  eComment: How to define operability in pulmonary hypertension secondary to congenital heart disease?

Authors:  Patrick O Myers; Frederic Lador; Maurice Beghetti
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-06

5.  The effect of distal pulmonary obstruction or elevated atrial pressures on pulmonary flow and pulmonary vascular disease: a mathematical flow circuit analogy model-based analysis.

Authors:  Balram Babu Rajanbabu; Raviraju Chigullapally
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-04-26

6.  Late presentation of aortopulmonary window: a contemporary series.

Authors:  Debasis Das; Nilanjan Dutta; Patralekha Das; Manish Kumar Sharma; Rangan Koley; Shubhadeep Das; Amitabha Chattopadhyay; Sanjiban Ghosh; Pradeep Narayan
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-01-08

Review 7.  Hypoxia signaling in human health and diseases: implications and prospects for therapeutics.

Authors:  Zhen Luo; Mingfu Tian; Ge Yang; Qiaoru Tan; Yubing Chen; Geng Li; Qiwei Zhang; Yongkui Li; Pin Wan; Jianguo Wu
Journal:  Signal Transduct Target Ther       Date:  2022-07-07

8.  The Challenges in Managing Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.

Authors:  Chun-Wei Lu
Journal:  Acta Cardiol Sin       Date:  2015-11       Impact factor: 2.672

9.  Tailored circulatory intervention in adults with pulmonary hypertension due to congenital heart disease.

Authors:  L E Couperus; I R Henkens; M R M Jongbloed; M G Hazekamp; M J Schalij; H W Vliegen
Journal:  Neth Heart J       Date:  2016-04-20       Impact factor: 2.380

Review 10.  Pulmonary hypertension: diagnostic and therapeutic challenges.

Authors:  Isabel S Bazan; Wassim H Fares
Journal:  Ther Clin Risk Manag       Date:  2015-08-17       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.